"With our China NPP Group Procurement Program, orphan and clinically urgent drugs can reach Chinese patients in months—not years—through fully compliant fast-track pathways," said Mike Zhou, CEO of ACA Pharma. Post this "China's pediatric and rare-disease hospitals are telling us clearly which therapies they need most, and our job is to turn those requests into practical, compliant access pathways," said Mike Zhou, CEO, ACA Pharma. "By combining group NPP access with 30–90 day Macau registration, we can he ...

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to extend its duration by one year to October 30, 2026, in response to significant dislocation in the trading price of its common stock [1][2] Summary by Sections Rights Plan Amendment - The amendment aims to increase potential dilution for any Acquiring Person if the Rights Plan is triggered, allowing stockholders to realize long-term value and reducing the likelihood of control by any person or group without proper compensation [2][4] - The Rights Plan will automatically expire on October 30, 2026, unless redeemed or exchanged earlier by the Company [4] Acquisition and Control - The Board did not adopt the extension in response to a specific takeover threat and retains the ability to engage with parties or accept acquisition proposals if deemed in the best interests of the Company and its stockholders [3] Rights Plan Details - The Rights become exercisable if an Acquiring Person acquires 10% or more of the outstanding common stock (15% for passive institutional investors) [4] - Stockholders above the threshold at the initial announcement are grandfathered but cannot increase ownership without triggering the Rights Plan [4] - Each Right allows the holder to purchase additional shares at $20.00, with a market value of twice the exercise price [4] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines, with a pipeline addressing underserved therapeutic areas [6]

Core Points - Eagle Pharmaceuticals, Inc. held its 2025 annual meeting of stockholders on October 17, 2025, with approximately 82% of shares represented [1] Group 1: Election of Directors - Two Class I nominees, Michael Graves and Richard Edlin, were elected to hold office until the 2027 Annual Meeting, receiving 8,113,749 and 8,053,759 votes in favor, respectively [2] - Two Class II nominees, Jennifer Simpson and Luciana Borio, were elected to hold office until the 2028 Annual Meeting, receiving 8,102,909 and 8,134,574 votes in favor, respectively [2] - The total number of broker non-votes was 1,064,408, and all nominees were successfully elected [2] Group 2: Appointment of Auditor - The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 9,011,921 votes in favor, 1,700,348 against, and 57,551 abstentions [3] - There were no broker non-votes recorded for this resolution [3] Group 3: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company involved in research and development, clinical, manufacturing, and commercial activities [4] - The company focuses on developing innovative medicines aimed at improving patients' lives, with a product portfolio that includes PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® [4] - Eagle's pipeline includes oncology and CNS/metabolic critical care product candidates targeting underserved therapeutic areas, emphasizing personalized medicine in cancer care [4]

Company Overview - Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial sectors [2] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [2] Product Portfolio - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [2] - The company has a pipeline focused on oncology and CNS/metabolic critical care, targeting underserved therapeutic areas across multiple disease states [2] Strategic Focus - Eagle is committed to developing medicines that have the potential to be integrated into the personalized medicine paradigm in cancer care [2]

Core Insights - Eagle Pharmaceuticals, Inc. has released its unaudited financial statements for the three months ended March 31, 2025, which are accessible on their investor relations website [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical trials, manufacturing, and commercialization [2] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [2] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (in Japan), and BYFAVO® and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [2] - The company's oncology and CNS/metabolic critical care pipeline features product candidates aimed at addressing underserved therapeutic areas across various disease states [2] - Eagle is focused on developing medicines that could integrate into the personalized medicine paradigm in cancer care [2]

Core Points - Eagle Pharmaceuticals, Inc. announced the availability of proxy materials for its 2025 Annual Meeting of Stockholders scheduled for October 17, 2025 [1] - The company is delivering a Notice of Internet Availability of Proxy Materials to stockholders of record as of August 18, 2025 [2] - The proxy materials, including the Notice, proxy information statement, and proxy card, are accessible online [2] - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines [3] - The company's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® [3] - Eagle's pipeline includes oncology and CNS/metabolic critical care product candidates aimed at addressing underserved therapeutic areas [3]

Core Viewpoint - Eagle Pharmaceuticals, Inc. has appointed Abhinav "Abi" Jain as an independent member of its Board of Directors, which is part of a cooperation agreement with Nantahala Capital Management, a significant shareholder holding approximately 38% of the company's outstanding shares [1][2]. Group 1: Appointment Details - Abhinav Jain will serve as a Class III director with an initial term expiring at the Company's 2026 Annual Meeting of Stockholders [1]. - Jain will also be a member of the Board's Compensation Committee and Nominating and Corporate Governance Committee [1]. - The cooperation agreement includes provisions for the appointment of a second independent director by May 15, 2026 [1][3]. Group 2: Background of Abhinav Jain - Jain is currently an Analyst at Nantahala, focusing on investments in specialty and generic pharmaceuticals [2]. - Prior to Nantahala, he was an Associate at Angelo, Gordon & Co., where he concentrated on private equity and structured credit investments [2]. - Jain holds a degree in Chemical-Biological Engineering from the Massachusetts Institute of Technology and an M.B.A. with honors in Finance and Entrepreneurial Management from The Wharton School [2]. Group 3: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company involved in research and development, clinical, manufacturing, and commercial activities [4]. - The company is dedicated to developing innovative medicines aimed at improving patients' lives, with a portfolio that includes products like PEMFEXY®, RYANODEX®, and others [4]. - Eagle's pipeline includes oncology and critical care candidates targeting underserved therapeutic areas, with a focus on personalized medicine in cancer care [4].

Core Points - Eagle Pharmaceuticals, Inc. will hold its 2025 Annual Meeting of Stockholders on October 17, 2025 [1] - The record date for stockholders to participate in the meeting is set for August 18, 2025, at 5 p.m. Eastern Time [1] Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial sectors [3] - The company is dedicated to developing innovative medicines that significantly improve patients' lives [3] - Eagle's commercialized products include PEMFEXY®, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM® (Japan), BYFAVO®, and BARHEMSYS® through its subsidiary Acacia Pharma Inc. [3] - The oncology and critical care pipeline includes product candidates aimed at addressing underserved therapeutic areas across multiple disease states [3] - The company focuses on developing medicines that could be integrated into the personalized medicine paradigm in cancer care [3]

Core Viewpoint - Eagle Pharmaceuticals has entered into a royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA for a total of $69 million before transaction costs, providing immediate capital to the company [1][3][4]. Group 1: Transaction Details - The agreement involves Eagle receiving an upfront payment of $69 million in exchange for a specified amount of its royalty interest in BENDEKA's net sales for the quarter ending December 31, 2024, and 100% of the royalty interest thereafter, capped at 1.3 times the purchase price [4]. - The proceeds from the transaction will be used to fully repay an existing credit agreement, including a $27.5 million term loan and $25 million under a revolving credit facility, with remaining funds allocated for general corporate purposes [5]. Group 2: Product Information - BENDEKA is a ready-to-dilute liquid formulation of bendamustine, approved for treating chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) [2]. - The product is characterized by its low-volume (50 mL) and short infusion time (ten minutes) [2]. Group 3: Company Strategy and Future Plans - The company continues to invest in its R&D programs, including CAL02 for severe community-acquired bacterial pneumonia and EA 114 for hormone-receptor-positive metastatic breast cancer [6]. - The transaction is seen as a strategic move to enhance the company's financial position and support ongoing research initiatives [3]. Group 4: Advisory and Legal Support - Armentum Partners, LLC acted as the financial advisor for Eagle on this transaction, while Latham & Watkins LLP provided legal counsel to Eagle, and Gibson, Dunn & Crutcher LLP represented Blue Owl [7]. Group 5: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company focused on developing innovative medicines with a portfolio that includes products like PEMFEXY®, RYANODEX®, and BENDEKA® [8]. - The company aims to address underserved therapeutic areas across multiple disease states and is committed to personalized medicine in cancer care [8].

Core Viewpoint - Eagle Pharmaceuticals, Inc. has amended its limited duration stockholder rights plan to increase the initial purchase price of each preferred share purchase right from $10.00 to $20.00, effective immediately, in response to significant dislocation in the trading price of its common stock [1][2]. Group 1: Rights Plan Details - The Rights Plan is designed to penalize any person or group acquiring 10% or more of the company's common stock without Board approval, with a higher threshold of 15% for passive institutional investors [2]. - The amendment increases the potential dilution an Acquiring Person would face if the Rights Plan is triggered, thereby protecting stockholders' long-term investment value [2]. - The Rights Plan will automatically expire on October 30, 2025, unless earlier redeemed or exchanged by the company [3]. Group 2: Company Overview - Eagle Pharmaceuticals is a fully integrated pharmaceutical company with expertise in research and development, clinical, manufacturing, and commercial operations [4]. - The company is focused on developing innovative medicines, particularly in oncology and critical care, with products like PEMFEXY®, RYANODEX®, and others in its pipeline [4].